Myelodysplastic Syndrome
News
Supportive Care and Hematologic Malignancies
(01/21/2008)
A Report from the 2007 American Society of Hematology (ASH) Meeting
Updates in the Management of Myelodysplastic Syndromes
(01/21/2008)
A Report from the 2007 American Society of Hematology (ASH) Meeting
Vidaza Improves Survival in High-risk Myelodysplastic Syndrome
(12/11/2007)
According to results recently presented at the 2007 annual meeting of the American Society of Hematology (ASH), the agent Vidaza® (azacitidine) improves survival among patients with high-risk myelodysplastic syndrome (MDS).
Myelodysplastic Syndrome: An Update from ASCO 2007
(10/12/2007)
At the 2007 American Society of Clinical Oncology (ASCO) meeting there were several interesting studies reported concerning supportive care issues in MDS, hypomethylating agents, growth factors, iron overload and prognostic factors.
Vidaza® Improves Survival in Myelodysplastic Syndromes
(08/06/2007)
According to a press release by Pharmion, Vidaza™ (azacitidine) significantly improves survival compared with conventional care in the treatment of myelodysplastic syndromes.
More
Myelodysplastic Syndrome
Cancer News...